Axogen, Inc. — 2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. This is an annual report; it does not provide standalone fourth-quarter results. Financial amounts below are in U.S. dollars.
Business context
Axogen develops and sells products for peripheral nerve repair, primarily in the U.S. Its principal products are Avance Nerve Graft and the Axoguard Nerve Connector, Protector and Cap. Avance generated approximately 60% of revenue. The company reported 968 active accounts and 332 core accounts at year-end; core accounts are defined as purchasing at least $100,000 over the prior 12 months.
Financial performance and liquidity
| Metric | 2022 | 2021 |
|---|---|---|
| Revenue | $138.6 million | $127.4 million |
| Revenue growth | 8.8% reported; 12.4% excluding 2021 Avive revenue | — |
| Gross profit / margin | $114.4 million / 82.6% | $104.4 million / 82.0% |
| Operating loss | $29.7 million | $25.4 million |
| Net loss | $28.9 million | $27.0 million |
| Loss per share, diluted | $0.69 | $0.65 |
| Cash used in operating activities | $16.1 million | $13.4 million |
Revenue excluding Avive increased $15.3 million, or 12.4%; management attributed growth mainly to higher unit volume, supported by core and active accounts, and changes in price and product mix. Gross margin rose 0.6 percentage points. Operating expenses increased 11.0% to $144.1 million, including higher compensation, research and development, travel and occupancy costs. The 2021 comparison included a $1.4 million Avive-related inventory and production-cost write-down.
At year-end, cash and cash equivalents were $15.3 million and short-term investments were $33.5 million, totaling $48.8 million; restricted cash of $6.3 million is separate. Working capital was $74.3 million, down from $102.8 million. Management said available cash, investments and expected product-sale proceeds should fund operations for at least 12 months from issuance of the financial statements. Cash, cash equivalents and restricted cash declined $17.5 million during 2022.
Capital expenditures were $20.1 million, largely related to the Axogen Processing Center (APC) renovation. The company had $50.0 million principal outstanding under its Oberland Capital credit facility, with maturities in 2027 and 2028. The stated interest rate was 11.24% at year-end, plus revenue-participation payments that management estimated add approximately 1.0% annually. Debt is secured by substantially all company assets; covenants were met at year-end. The lender’s and company’s differing interpretations of a make-whole calculation could produce estimated payments at scheduled maturity of up to approximately $9 million on the first tranche and $4 million on the second under the lender’s alternative interpretation.
Material changes, outlook and risks
- Avance BLA: The RECON Phase 3 study met its primary endpoint; reported results showed statistical superiority to conduits on certain sensory-function measures in specified nerve-gap subgroups. Axogen planned to submit a Biologics License Application by the end of 2023. Avance remained marketed under FDA enforcement discretion and a transition plan; the FDA could restrict distribution, require further evidence or decline the BLA.
- Manufacturing transition: The company expected APC renovation and validation to finish in the first half of 2023, with processing transfer beginning around mid-2023 and before the CTS agreement’s December 31, 2023 termination date. It anticipated $3.5–$4.5 million of APC spending in 2023, in addition to ordinary annual capital expenditures of approximately $4–$5 million. Timing, validation, execution and projected efficiencies remain uncertain.
- Cash burn and financing: Axogen had a history of losses and negative operating cash flow and said losses could continue. Additional financing may be needed; availability and terms are uncertain, and equity financing could dilute shareholders. The credit facility includes financial covenants, revenue-based payments and potential acceleration upon specified events.
- Banking event: At March 14, 2023, approximately $8.0 million had been held at Silicon Valley Bank. The filing states the company had access to all SVB funds by that date and had arranged to transfer accounts and other cash and investments to JPMorgan Chase; transition-related payment disruption remained a stated risk.
- Other dependencies: Revenue depends substantially on four products, with Avance concentration; Axoguard supply and distribution depend on Cook Biotech. The company also cited reimbursement coverage, donor-tissue availability, third-party suppliers, competition, inflation, labor and supply-chain pressures as risks. Avive remained off the market since June 2021 while regulatory discussions continued; no return timeline or assurance was provided.
- Grants and contingencies: APC-related grants are subject to job-creation milestones and clawback provisions. Axogen had requested extensions and had not received a decision. The company also disclosed ordinary-course legal matters; management did not expect them to have a material adverse effect, and the securities class action dismissal was affirmed on appeal in August 2022.
The filing gives no quantified revenue or earnings guidance for 2023. Management’s stated priorities and expectations included sales-force productivity, continued investment in product development and clinical work, BLA submission, and the APC transition. The independent auditor issued an unqualified opinion on the financial statements and internal control over financial reporting; inventory valuation was identified as a critical audit matter.
Important facts for investors to verify
- Whether and when the Avance BLA is submitted and accepted, and whether the FDA permits continued marketing and approves the proposed labeling.
- APC construction, validation, regulatory readiness and transfer milestones, including any effect on production, supply, costs or cash needs.
- Operating cash burn, cash and investment balances, and the company’s funding runway as capital spending and debt payments continue.
- The credit facility’s make-whole interpretation, revenue-participation burden, interest terms and covenant headroom.
- Reimbursement coverage and adoption trends, particularly given Avance’s approximately 60% revenue contribution and the company’s reported account concentration.
- The filing reports 2022 research and development expense of $27.2 million in its results table, while another business-section passage says approximately $24.2 million; verify the intended comparable figure.